ACEA Biosciences
Latest round
- Series E
Last raised
- Apr 2016
Total raised
- Undisclosed
Investors
- 1
About ACEA Biosciences
ACEA Biosciences, Inc.Founded in 2002 and headquartered in San Diego, US, ACEA Biosciences, Inc. focuses on developing flow cytometry and live cell analysis solutions. In September 2018, the company was acquired by Agilent Technologies Inc. for USD 250 million.ACEA Biosciences, now part of Agilent, specializes in advanced flow cytometry and real-time live cell analysis solutions tailored for research applications in areas such as immunotherapy, infectious diseases, and drug discovery. The core product offerings include Agilent's NovoCyte flow cytometers and xCELLigence Real-Time Cell Analysis (RTCA) instruments. The NovoCyte flow cytometers provide researchers with high-quality data in an intuitive platform, facilitating the acquisition and analysis of experimental data. The xCELLigence RTCA instruments utilize biosensors to monitor cell behavior in a label-free manner, enabling users to track immune cell activity and virus-induced cytopathic effects in real time.ACEA Biosciences generates revenue primarily through the sale of its flagship products, including the NovoCyte series and xCELLigence RTCA instruments, which are sold directly to clients in the research and healthcare sectors. The company operates on a B2B model, engaging directly with universities, research institutions, and pharmaceutical companies. Transactions typically involve the purchase of lab instruments along with optional reagents and software, creating a comprehensive solution for clients' experimental needs.The recent acquisition by Agilent Technologies provides ACEA Biosciences the opportunity to leverage additional resources for future growth. Although specific new product launches have not been detailed, the integration into Agilent is expected to enhance their product portfolio in cell analysis technologies. ACEA is well-positioned to expand into new markets, particularly in Asia, where there is increasing demand for sophisticated research tools. The USD 250 million from the acquisition will support these initiatives, allowing for investment in R&D and market expansion.
Who invested in ACEA Biosciences
1 investor across 1 round
See all investors in ACEA Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
Apr 1, 2016
Amount
Undisclosed
Investors
Questions about ACEA Biosciences
Who invested in ACEA Biosciences?
ACEA Biosciences has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ACEA Biosciences raised?
ACEA Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ACEA Biosciences last raise money?
ACEA Biosciences's most recent round on record is a Series E, in Apr 2016.
What does ACEA Biosciences do?
ACEA Biosciences is a biotechnology company.
Where is ACEA Biosciences headquartered?
ACEA Biosciences is headquartered in San Diego, US.
Which VCs invest in companies like ACEA Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ACEA Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like ACEA Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.